CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults

Allergy, Asthma & Clinical Immunology

Audrey O Segal²  Anne K Ellis¹  Harold L Kim³ 

[1] Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON, Canada

[2] Department of Paediatrics, Rouge Valley Health System, Toronto, ON, Canada

[3] Division of Allergy & Immunology, Department of Medicine, McMaster University, Hamilton, ON, Canada

关键词: Drug safety;    Lymphoma;    Pimecrolimus;    Tacrolimus;    Therapy;    Topical corticosteroids;    Atopic dermatitis;   

Others  :  792225
DOI  :  10.1186/1710-1492-9-24

 received in 2013-05-02, accepted in 2013-06-11,  发布年份 2013

【 摘 要 】

Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Arming ourselves with appropriate and safe treatment modalities to provide relief for this chronic and relapsing inflammatory condition is of utmost importance to our patients and their families. Utilizing topical calcineurin inhibitors (TCIs) for the treatment of AD not responsive to high-potency corticosteroids, or low-potency corticosteroids and localized to the face, eyelids, and skin folds of patients >2 years, is reasonable to include in common practice. Despite the FDA’s Black Box warning, to date no evidence has been published linking the TCIs to an increased incidence of malignancy in either children or adults that establishes causation. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recognizes that the benefits of TCIs should be carefully weighed with the theoretical risks in advising patients, and acknowledges that long-term studies remain in progress. The safety and efficacy of topical tacrolimus and pimecrolimus should therefore be considered when treating children and adults with AD in Canadian allergy and immunology practices.

【 授权许可】

   
2013 Segal et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003, 112(suppl):S118-S127.
• [2]Watson W, Kapur S: Atopic dermatitis. Allergy Asthma Clin Immunol 2011, 7(suppl 1):S4. BioMed Central Full Text
• [3]Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ: The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008, 58:68-73.
• [4]Williams HC: Atopic dermatitis. NEJM 2005, 352:2314-2324.
• [5]Bieber T: Atopic dermatitis. Ann Dermatol 2010, 22:125-137.
• [6]Leung DY, Nicklas RA, Li JT, Bernstein IL, Blessing-Moore J, Boguniewicz M, Chapman JA, Khan DA, Lang D, Lee RE, Portnoy JM, Schuller DE, Spector SL, Tilles SA: Disease management of atopic dermatitis: an updated practice parameter. JointTask Force on Practice Parameters. Ann Allergy Asthma Immunol 2004, 93(Suppl 2):S1-S21.
• [7]Breuer K, Werfel T, Kapp A: Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005, 6:65-77.
• [8]de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G: Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol 1991, 147:4278-4285.
• [9]Fleischer AB, Boguniewicz M: An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 2010, 9:488-498.
• [10]Frankel HC, Qureshi AA: Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012, 13:113-123.
• [11]Food and Drug Administration Pediatric Advisory Committee. February 15, 2005, Briefing Information. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm webcite
• [12]Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Paller A, de Prost Y, Puig L, Ring J, Saurat JH, Schwartz T, Shear N, Stingl G, Taieb A, Thestrup-Pedersen K: Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005, 211:77-78.
• [13]Canadian Dermatology Association (CDA): Position Statement on Topical Calcineurin Inhibitors (media release). April 2005.
• [14]Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, Boguniewicz M, Leung DY: Report of the topical calcineurin task force of the ACAAI and AAAAI. J Allergy Clin Immunol 2005, 115:1249-1253.
• [15]Ori Y, Herman-Edelstein M, Zingerman B, Rozen-Zvi B, Gafter U, Malachi T, Gafter-Gvili A: Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells. Biomed Pharmacother 2012, 66:409-413.
• [16]Kothary N: Update on post-marketing AERS cases of pediatric malignancies reports with topical pimecrolimus and tacrolimus use. Food and Drug Administration Pediatric Advisory Committee. May 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255412.pdf webcite
• [17]Tennis P, Gelfand JM, Rothman KJ: Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011, 165:465-473.
• [18]Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007, 127:808.16.
• [19]Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD: Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009, 219:7-21.
• [20]McCollum AD, Paik A, Eichenfield LF: The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol 2010, 27:425-436.
• [21]Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M: Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother 2009, 43:1956-1963.